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ORIGINAL ARTICLE
Modulation of VEGF-induced migration and network formation by
lymphatic endothelial cells: Roles of platelets and podoplanin
Stacey A. Langan, Leyre Navarro-Núñez, Steve P. Watson, & Gerard B. Nash
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Abstract
Lymphatic endothelial cells (LEC) express the transmembrane receptor podoplanin whose only
known endogenous ligand CLEC-2 is found on platelets. Both podoplanin and CLEC-2 are
required for normal lymphangiogenesis as mice lacking either protein develop a blood-lym-
phatic mixing phenotype. We investigated the roles of podoplanin and its interaction with
platelets in migration and tube formation by LEC. Addition of platelets or antibody-mediated
crosslinking of podoplanin inhibited LEC migration induced by vascular endothelial growth
factors (VEGF-A or VEGF-C), but did not modify basal migration or the response to basic
fibroblast growth factor or epidermal growth factor. In addition, platelets and podoplanin
crosslinking disrupted networks of LEC formed in co-culture with fibroblasts. Depletion of
podoplanin in LEC using siRNA negated the pro-migratory effect of VEGF-A and VEGF-C.
Inhibition of RhoA or Rho-kinase reduced LEC migration induced by VEGF-C, but had no
further effect after crosslinking of podoplanin, suggesting that podoplanin is required for
signaling downstream of VEGF-receptors but upstream of RhoA. Together, these data reveal
for the first time that podoplanin is an intrinsic specific regulator of VEGF-mediated migration
and network formation in LEC and identify crosslinking of podoplanin by platelets or anti-
bodies as mechanisms to modulate this pathway.
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Introduction
During development of the lymphatics, endothelial cells of the
cardinal vein commit to a lymphatic phenotype, expressing a
number of markers including vascular endothelial growth factor
receptor 3 (VEGFR3) [1–3]. These lymphatic endothelial cells
(LEC) then migrate away from the cardinal vein in a VEGF-C
dependent manner [4] to form the primordial thoracic duct,
acquiring podoplanin expression during the process. Further
sprouting from these nascent structures and subsequent remodel-
ing creates the rest of the lymphatic network.
Podoplanin is the only known ligand for the platelet receptor
CLEC-2, and previous studies have shown that both are necessary
for the correct development of the lymphatic vasculature [5–7].
Mutant mice lacking either of these proteins displayed a pheno-
type in which blood was detected in lymphatic vessels. Similarly,
mice lacking signaling proteins known to be downstream of
CLEC-2, including Syk, SLP-76, and PLCγ2, displayed a blood-
lymphatic mixing phenotype [8–11]. The platelet-specific role for
CLEC-2 was confirmed by the creation and studies of lymphan-
giogenesis in Clec1bfl/flPF4-Cre mice [12,13]. These studies also
showed that platelets from mice expressing CLEC-2 inhibited the
migration and formation of networks of LEC on matrigel, while
platelets isolated from mice lacking expression had a significantly
weaker inhibitory effect in both assays [12,13].
In comparison with CLEC-2 in platelets, signaling down-
stream of podoplanin in LEC has not been well described. The
cytoplasmic domain of podoplanin consists of only nine amino
acids, but contains a sequence of three basic amino acids that are
necessary for interaction with the ezrin/radixin/moesin (ERM)
protein family [14,15]. ERM proteins connect membrane-bound
proteins to the actin cytoskeleton and are involved in signaling
pathways that control cell migration and adhesion [16].
Overexpression of podoplanin in Madin-Darby canine kidney
(MDCK) cells promoted migration and increased the amount of
active RhoA, which was associated with an increase in phosphor-
ylation of ERM proteins, leading the authors to conclude that
podoplanin phosphorylates ERM proteins via RhoA and its effec-
tor protein, Rho kinase (ROCK) [15]. Conversely, it has been
shown that siRNA-mediated knockdown of podoplanin in LEC
reduced the ability of these cells to migrate across a wound or
form networks on Matrigel [17,18]. Podoplanin knockdown was
associated with a reduction in active RhoA and treating LEC with
an inhibitor of RhoA was able to prevent network formation [17].
However, podoplanin knockdown had no effect on the amount of
phosphorylated nor basal ERM proteins in LEC [17].
VEGF-C is a critical regulator of lymphangiogenesis whose
absence results in a lack of lymphatic vessels and embryonic
lethality [19–21]. A similar phenotype was observed in mice
that had a mutation encoding a tyrosine kinase inactive
VEGFR3 [22]. Conversely, overexpression of VEGF-C can
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increase lymphatic growth in adult tissues and is also thought to
promote inflammation-induced lymphangiogenesis in the adult
[23,24]. VEGF-C has multiple splice variants and its affinity for
VEGFR3 increases with each processing step. Mature, fully pro-
cessed VEGF-C is able to bind to VEGFR2 as well as VEGFR3
[25]. Soluble VEGFR3 or VEGFR3-blocking antibodies prevent
the maturation of lymphatic capillaries during embryonic devel-
opment and the early postnatal period, but have no effect on
established vessels [26,27]. However, administration of
VEGFR2- or VEGFR3-blocking antibodies to adult mice prevents
lymphangiogenesis in areas of wound healing [28]. LEC express
both VEGFR2 and VEGFR3 [29] and interaction between VEGF-
C and VEGFR3 [30], or between VEGFA and VEGFR2 [31] have
both been reported to increase LEC migration.
The above suggests that podoplanin and VEGF-mediated sig-
naling both regulate LEC migration and that both are required for
mature lymphangiogenesis as well as embryonic formation of the
lymphatics. However, the link between the two pathways has not
been fully explored. Moreover, the role of platelets in formation
of lymphatics and their ability to alter behavior of LEC suggests
that crosslinking of podoplanin by CLEC-2 further regulates this
axis.
To investigate further, we analyzed the effects of platelets,
podoplanin crosslinking by antibodies, and podoplanin knock-
down by siRNA on migration of LEC through micropore filters,
and on the stable tube-like networks of LEC formed when they
were co-cultured with human dermal fibroblasts. We found that
antibody-mediated crosslinking of podoplanin inhibited migration
and network formation by LEC in a similar manner to platelets.
Reduction in expression of podoplanin independently reduced the
effects of platelets and of responses to VEGFA or VEGFC on
migration, but not basal migration or increases induced by other
growth factors. Inhibition of RhoA or Rho-kinase also inhibited
VEGF-induced migration, but crosslinking of podoplanin had no
additional effects, suggesting that podoplanin was linked to RhoA
downstream of VEGFR signaling. Thus, podoplanin intrinsically
and specifically regulates responses to different VEGF family
members, while crosslinking of podoplanin through platelets or
otherwise likewise may influence the development and stability of
forming lymphatic vessels.
Materials and methods
Ethics statement
The work described here was performed with the ethical approval
of the Science, Technology, Engineering, and Mathematical
Ethical Review Committee of the University of Birmingham.
All blood donors were adult volunteers who had given informed
consent. All animal work was performed under a UK Home
Office license.
Cell culture
Human dermal primary LEC and human primary dermal fibro-
blasts (HDF) were from PromoCell (Heidelberg, Germany). The
HMEC-1 cell line was obtained from the Centre for Disease
Control and Prevention (CDC; Atlanta, Georgia, USA). LEC
and HDF were cultured in MV2 and FGM2, respectively (both
PromoCell). HMEC-1 were cultured in M199 (Gibco, Paisley,
UK) that was supplemented with 20% foetal calf serum (Sigma,
Poole, UK). With the exception of siRNA transfections, cells were
treated with 2.5µg/ml amphotericin (Gibco), 100U/ml penicillin
and 100µg/ml streptomycin (both Sigma). All cells were cultured
at 37°C and 5% CO2 and 95% air.
Platelet preparation
Whole blood was drawn into anticoagulant citrate phosphate
dextrose adenine (CPDA; pH 7.4; Sigma) at a ratio of 1:9.
Washed human platelets were isolated using theophylline, as
previously described [32]. Mouse blood was drawn from the
vena cava into 10% ACD. Washed platelets were isolated by
centrifugation, and platelet activation was prevented using pros-
tacyclin. The full methods have been described previously
[33,34]. In some experiments, platelets were derived from mice
deficient in CLEC-2 (Clec1b-/-) previously described [12].
Conditional deletion of CLEC-2 was achieved by insertion of
loxP sites flanking exons 3 and 4 of the Clec1b gene (Clec1bfl/
fl), using standard methods. Cre-mediated recombination of the
Clec1bfl allele results in deletion of exons 3 and 4, and a frame-
shift in exons 5 and 6 (Clec1bfl/flPF4-Cre).
siRNA transfections and flow cytometry
LEC were seeded onto 24-well plates in antibiotic-free medium.
Transfections were performed the following day, when cells were
around 80% confluent. Two validated siRNA duplexes targeting
podoplanin (siRNA ID: 1. SASI_Hs01_00094891 and 2.
SASI_Hs01_00192618) and a nonspecific control (Universal
negative control #1SIC001) were purchased from Sigma.
Duplexes were diluted in Optimem (Gibco) to give a final con-
centration of 10-70nM when added to cells. In a separate tube,
10% RNAiMAX lipofectamine (Invitrogen, Paisley, UK) in
Optimem was prepared. Both solutions were incubated at room
temperature for 10 minutes, then combined and incubated for a
further 10 minutes. About 500µl diluted duplex was added to each
well. The plate was incubated at 37°C and 5% CO2 for 4 hours,
before the transfection mix was replaced with antibiotic-free
medium and incubated for a further 24-72 hours.
Expression of podoplanin, VEGFR2, and VEGFR3 was quan-
tified by flow cytometry. Cells were detached with Accutase
(Gibco) and stained with PE-conjugated antibodies against
human podoplanin (0.125µg; clone NZ-1.3; eBioscience,
Hatfield, UK), VEGFR2 (1:7.5; 89106; R&D Systems,
Abingdon, UK) or VEGFR3 (1:7.5; 54733; R&D Systems) or
an appropriate control (0.125µg rat IgG2a; eBioscience; 1:7.5
mouse IgG1; Immunotools, Friesoythe, Germany). Samples were
protected from light and incubated on ice for 40 minutes. Samples
were diluted with 300µl PBS before analysis on a FACSCalibur
flow cytometer (BD Bioscience, Oxford, UK). Data were ana-
lyzed using Summit v4.3 (Dako, Colorado, USA), to obtain
values for percent positive (above isotype control) and median
fluorescence intensity (MFI).
Analysis of cell migration
3x104 endothelial cells were seeded onto polyethylene terephtha-
late cell culture inserts with 8µm pores (BD Biosciences). These
were placed in 24-well plates with culture medium, 300ng/ml
VEGF-C, 30ng/ml VEGF-A (both R&D Systems), 10ng/ml
basic fibroblast growth factor (bFGF; Peprotech; London, UK),
or 20ng/ml epidermal growth factor (EGF; Sigma) in the lower
chamber of the well. The plates were incubated for an hour at 37°
C and 5% CO2 before the addition of washed platelets. In podo-
planin-crosslinking experiments, LEC were incubated on the
inserts for 30 minutes at room temperature before addition of
2µg/ml rat IgG2a or anti-human podoplanin (NZ-1.3;
eBioscience, Hatfield, UK). The plate was incubated at room
temperature for 30 minutes before addition of 30µg/ml anti-rat
IgG2a (eBioscience) to induce crosslinking.
2 S. A. Langan et al. Platelets, Early Online: 1–10
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In experiments where the effects of antibodies against
VEGF-receptors were tested, endothelial cells were seeded for
30min and antibodies against VEGFR2 (IMC-1121b), VEGFR3
(IMC-3C5; both 5µg/ml, gifts of Eli Lilly and Company, New
York, USA), or both were added for 30min before addition of
VEGFA or VEGFC.
Where inhibitors of RhoA or ROCK were used, podoplanin
was crosslinked when appropriate and the plate was incubated at
room temperature for 30 minutes before the addition of 4µg/ml
CT04 (Cytoskeleton Inc., Colorado, USA) or 100µM Y27632
(Calbiochem, Nottingham, UK), respectively, and incubated for
12 or 24 hours. Initial studies compared effects of 10 and 100µM
Y27632 directly on LEC migration and showed a dose-dependent
effect which was greater and significant at the higher concentra-
tion; and this concentration was used thereafter and in experi-
ments reported below.
At the end of all migration experiments, cells were washed
with PBS, fixed with 2% formaldehyde and their nuclei stained
with 2µg/ml bisbenzimide (Sigma). The stained nuclei were
imaged using an invert fluorescent microscope (AxioVert 200M;
Zeiss, Hertfordshire, UK). The numbers of cells above and below
the insert were counted in 12 fields per filter, with each condition
in each experiment tested in duplicate wells and averaged.
Percentage transmigration was calculated as follows:
Percentage migration ¼ Number of migrated cells
Total number of cells
 100
Formulation of tubes in LEC–HDF co-cultures
3x104 HDF were seeded onto wells of a 12-well plate and cul-
tured until confluent (typically four days). LEC were stained with
5µM Cell Tracker Green (Life Technologies, Paisley, UK). 3x104
stained LEC were seeded onto each confluent well of HDF. The
co-cultures were maintained in MV2 medium with or without
300ng/ml VEGF-C for three days. Images were taken using the
10x objective of an invert fluorescent microscope (Olympus,
Southend-on-Sea, UK). 2x108 washed platelets were added to
the co-cultures, or podoplanin was crosslinked, as described
above. The cells were co-cultured for a further 24 hours before
additional fluorescent images were taken. Images were analyzed
offline using ImageJ 1.49 (NIH, Bethesda, Maryland, USA). The
segmented line tool was used to draw along each tube; the length
of the tube was then measured.
Statistical analysis
Variation between multiple treatments was evaluated using ana-
lysis of variance (ANOVA). In cases showing significant varia-
tion, post hoc comparisons were made to control by Dunnett test
or between conditions by Bonferroni test. Effects of single treat-
ments were analyzed by paired t-test compared to controls.
Results
Characterization of podoplanin expression by lymphatic
endothelial cells
Flow cytometry showed that LEC were >90% positive for expres-
sion of podoplanin and HMEC-1 ~50% positive, although a smaller
proportion actually fell under the nonspecific labeling peak
(Figure 1A). The effects of siRNA transfection at 30-70nM on
podoplanin expression by LEC were similar, as were the effects
of the two different siRNAs. After 24h, we found approximately
Figure 1. Expression of podoplanin on lymphatic endothelial cells and
effect of platelets on their migration. A) Flow cytometer, frequency
distributions of fluorescence intensity for LEC and HMEC-1 labeled
with antibody against podoplanin (PDPN). B) Effect on migration when
different numbers of platelets were added to LEC which had been settled
onto a Transwell filter, with or without treatment with VEGF-C (300 ng/
ml). The percentage of the LEC which had transmigrated after 24h was
analyzed. Data are mean ± SEM from four experiments. ANOVA showed
significant effects of VEGF-C and of platelet count (p < 0.01 in each
case). **=p < 0.01 compared to 0 platelets by Dunnett’s test, for VEGF-
C-treated LEC. C) Effect on migration when platelets (108) were added to
HMEC-1 which had been settled onto a Transwell filter, with or without
treatment with VEGF-C (300 ng/ml). The percentage of the HMEC-1
which had transmigrated after 24 h was analyzed. Data are mean ± SEM
from three experiments. ANOVA showed significant effects of VEGF-C
and of platelets (p < 0.01 in each case). **=p < 0.01 compared to 0
platelets by Dunnett’s test, for VEGF-C-treated LEC.
DOI: https://doi.org/10.1080/09537104.2017.1336210 Modulation of vegf-induced migration and network formation 3
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50% reduction in surface expression and this remained essentially
constant up to 72h. Combining the two siRNA did not reduce
expression further. For subsequent functional experiments, we
used siRNA1 at 30nM and carried out functional analyses 48h
after transfection when MFI was 43 ±4% of control (mean ±
SEM, n=6).
Effect of platelets on migration of lymphatic endothelial
cells
The effect of platelets on LEC migration was assessed using the
transfilter migration assay. Washed human platelets had no effect
on migration in the absence of VEGF-C but inhibited the increase
in migration induced by VEGF-C in a count-dependent manner
(Figure 1B). Platelets also inhibited VEGF-C-promoted migration
of HMEC-1 (Figure 1C), an immortalized endothelial cell line
which we and others [35] have found to express podoplanin. In
each type of cell, 108 platelets completely inhibited the pro-
migratory effect of added VEGF-C. However, the effect of
VEGF was itself greater for LEC (increase above baseline 64 ±
4%; mean ± SEM of four independent experiments) than for
HMEC-1 (increase above baseline 46 ± 8%; mean ± SEM of
three independent experiments). This suggests that the effect of
VEGF-C was greater for cells with greater expression of podo-
planin. The more puzzling observation that platelets were able to
completely down-regulate VEGF-mediated migration even for
HMEC-1 that expressed podoplanin at a lower and non-uniform
level would seem to require that only cells expressing podoplanin
above a threshold level could respond to VEGF-C. We thus
examined the role of podoplanin in supporting the effect of
VEGF-C further.
Effects of crosslinking or knock-down of podoplanin on
migration of LEC induced by VEGF
Platelets may have exerted their effects on LEC through clustering
podoplanin. We thus tested the effect of crosslinking podoplanin,
using an antibody against podoplanin (clone NZ-1.3) and an
appropriate secondary antibody. Podoplanin crosslinking inhib-
ited LEC migration in the presence of VEGF-C (Figure 2A).
Consistent with the effects of platelets, crosslinking podoplanin
had no effect on LEC migration in the absence of VEGF-C. Anti-
podoplanin or nonspecific rat IgG alone had no effect on LEC
migration; similarly, combining nonspecific IgG with the second-
ary antibody did not alter migration (Figure 2A).
To confirm whether the effect of podoplanin crosslinking was
specific to effects of VEGF on migration, transfilter assays were
performed in the presence of VEGF-C, bFGF, and EGF. All three
growth factors were able to promote LEC migration, but podo-
planin crosslinking only inhibited migration in the presence of
VEGF-C (Figure 2B).
Since these results implied that podoplanin crosslinking by
platelet or antibodies inhibited VEGF-mediated signaling, we
investigated the specificity of the effects for different members
of the VEGF family and their receptors. VEGF-A and VEGF-C
each promoted transmigration of LEC (Figure 3A,B). Antibody
against VEGFR2 effectively inhibited the increase induced by
VEGF-A and partially reduced the effect of VEGF-C, whereas
antibody against VEGFR-3 effectively inhibited the increase
induced by VEGFC and partially reduced the effect of VEGFA
(Figure 3A, B). Combination of antibodies did not reduce migra-
tion further than the more effective antibody alone. Next, we
tested the effects of crosslinking podoplanin for each isoform.
Crosslinking reduced migration promoted by either VEGF-A or
VEGF-C to the basal unstimulated level (Figure 3C). These
results suggest that pro-migratory effects of VEGF-A and
VEGF-C and signals through VEGFR-2 and VEGFR-3 were
inhibited by crosslinking podoplanin.
To further test the role for podoplanin in cell migration, siRNA
was used to deplete podoplanin on LEC. The podoplanin-knock-
down cells were then used in transfilter assays, with or without
added platelets. In the absence of VEGF-C, neither podoplanin
knockdown nor platelets had an effect on basal migration
(Figure 4A). In the presence of VEGF-C, platelets inhibited migra-
tion of LEC that had not been transfected and cells that had been
transfected with nonspecific siRNA. When podoplanin siRNA was
transfected, VEGF-C no longer promoted that migration and plate-
lets were not able to further inhibit migration (Figure 4A). Similarly,
Figure 2. Effects of podoplanin crosslinking on LEC migration. A) LEC
settled onto a Transwell filter were treated with antibody against podo-
planin or a nonspecific IgG, with or without a crosslinking secondary
antibody, with or without treatment with VEGF-C (300 ng/ml). The
percentage of the LEC which had transmigrated after 24 h was analyzed.
Data are mean ± SEM from three experiments. ANOVA showed signifi-
cant effects of VEGF-C and of antibody treatment (p < 0.01 in each
case). **=p < 0.01 compared to no antibodies by Dunnett’s test, for
VEGF-C-treated LEC. B) LEC settled onto a Transwell filter were treated
with VEGF-C (300 ng/ml), FGFb (10 ng/ml) or EGF (20 ng/ml), with or
without antibodies to induce crosslinking of podoplanin. The percentage
of the LEC which had transmigrated after 24h was analyzed. Data are
mean ± SEM from at least three experiments. **=p < 0.01 by paired t
test.
4 S. A. Langan et al. Platelets, Early Online: 1–10
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VEGF-Awas not able to promote migration of LEC after podoplanin
knockdown (Figure 4B). The effect of platelets was likely due to
ligation of podoplanin by CLEC-2. We tested this possibility by
Figure 4. Effects of podoplanin knockdown or of platelets lacking CLEC-
2 on LEC migration. A) LEC settled onto a Transwell filter were treated
with or without platelets (108), with or without siRNA targeting podo-
planin, with or without treatment with VEGF-C (300 ng/ml). The percen-
tage of the LEC which had transmigrated after 24 h was analyzed. Data
are mean ± SEM from three experiments. ANOVA showed significant
effects of VEGF-C, siRNA treatment and platelet treatment (p < 0.01 in
each case). **=p < 0.01 compared to nonspecific siRNA by Dunnett’s
test, for VEGF-C-treated LEC. B) LEC settled onto a Transwell filter
were treated with or without siRNA targeting podoplanin, with or without
treatment with VEGF-A (30 ng/ml). The percentage of the LEC which
had transmigrated after 24 h was analyzed. Data are mean ± SEM from at
least three experiments. ANOVA showed significant effects of VEGF-A
and of siRNA treatment (p < 0.01 in each case). **=p < 0.01 compared
to nonspecific siRNA by Dunnett’s test, for VEGF-A-treated LEC. C)
Platelets (108) were added to LEC which had been settled onto a
Transwell filter in the presence of VEGF-C (300 ng/ml). The platelets
were from Clec1bfl/fl (CLEC-2+) or Clec1bfl/flPF4-Cre (CLEC-2−)
mice. Wells without platelets received 100μl Ca2+/Mg2+-free sterile
PBS. The percentage of the LEC which had transmigrated after 24h
was analyzed. Data are mean ± SEM from at least four experiments.
ANOVA showed that platelets had a significant effect (p < 0.01). ** = p
< 0.01 by Bonferroni post-test.
Figure 3. Effects of different types of VEGF on LEC migration: inhibition
by antibodies against VEGF-R and by podoplanin crosslinking. A,B)
Antibodies against VEGFR-2, VEGFR-3, or both were added to LEC settled
onto a Transwell filter, with or without treatment with (A) VEGF-A (30 ng/
ml) or (B) VEGF-C (300 ng/ml). The percentage of the LEC which had
transmigrated after 24h was analyzed. Data are mean ± SEM from four
experiments. ANOVA showed significant effects of VEGF and of antibody
treatment (p < 0.01 in each case). *=p < 0.05, **=p < 0.01 compared to no
antibodies by Dunnett’s test, for VEGF-treated LEC. C) LEC settled onto a
Transwell filter were treated with VEGF-A or VEGF-C, with or without
antibodies to induce crosslinking of podoplanin. The percentage of the LEC
which had transmigrated after 24 h was analyzed. Data are mean ± SEM
from six experiments. ANOVA showed significant effects of VEGF and of
crosslinking (p< 0.01 in each case).). *=p< 0.05, **=p< 0.01 compared to
no crosslinking by Bonferroni test, for VEGF-treated LEC.
DOI: https://doi.org/10.1080/09537104.2017.1336210 Modulation of vegf-induced migration and network formation 5
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comparing effects of platelets from mice expressing or lacking
expression of CLEC-2 (Clec1bfl/fl or Clec1bfl/flPF4-Cre mice,
respectively). We found that the murine CLEC-2+ platelets sup-
pressed transmigration, and this effect was significantly less (but
not abolished) with the platelets lacking CLEC-2 (Figure 4C). The
results support the conclusions that effects of platelets through
podoplanin were mediated through CLEC-2.
To determine whether the loss of effect of VEGF was due to a
change in receptor expression, flow cytometry was used to quantify
cell surface levels of VEGFR2 and VEGFR3. We found that trans-
fection of siRNA into LEC had no significant effect on surface
expression of VEGFR2 or VEGFR3 (values 85±7% or 84±13% of
control; mean ±SEM, n=3). These results suggest that podoplanin is
a novel regulator of VEGF-mediated responses in LEC.
Effects of platelets and podoplanin crosslinking on stability
of LEC networks
Having shown that platelets and podoplanin crosslinking modulate
VEGF-mediated LEC migration, we also examined their effects on
networks of LEC, adapting a method described for vascular endothe-
lial cells [36–38] but not yet reported for LECs. We found for the first
time that stable networks of LEC could be established on monolayers
of fibroblasts. Networks of LEC formed within 72 hours, with little
further growth beyond this time (Figure 5A). With added VEGF-C,
networks tended to be more stable and extensive than without
(Figure 5B). It was shown previously that fibroblasts in this co-culture
assay produced VEGF and that inhibition of VEGF-R reduced tube
formation even when no exogenous VEGF was added [36]. This
indicates that any effect of platelets or podoplanin on networks could
not be studied independent of VEGF. Since VEGF is intrinsic to the
assay, we added VEGF-C to obtain as standard conditions as possible
under which to test the effects podoplanin ligation or crosslinking. To
assess the effects of platelets on tube formation, LECwere co-cultured
with HDF and VEGF-C for three days to allow networks to form and
then incubated with platelets for 24 hours. The LEC became rounded
and the previously detected networks disintegrated (Figure 6A).
Similarly, podoplanin crosslinking induced network disintegration,
which was not seen in wells treated with a rat IgG and appropriate
secondary (Figure 6B). Quantitation of tube length in both conditions
confirmed that platelets and podoplanin crosslinking significantly
disrupted previously formed networks of LEC within 24 hours
(Figure 6C, D). Thus, podoplanin appears able to regulate stability of
lymphatic vessels aswell as cellmigration required for their formation.
Investigation of signaling downstream of VEGF-R and
podoplanin
Since podoplanin appeared to modify signals downstream of
VEGF-R, we investigated whether podoplanin was linked to, or
independent of, small GTPase signaling, also likely to regulate
migration responses. Inhibitors of RhoA (CT04) and of Rho
kinase (Y27632) were used in combination with podoplanin
crosslinking. We found that CT04 had little effect on unstimulated
migration but inhibited migration induced by VEGF-C in a simi-
lar manner to podoplanin crosslinking (Figure 7A). However,
CT04 did not further reduce migration when combined with
podoplanin crosslinking. Similarly, Y27632 inhibited migration
induced by VEGF-C, but did not further reduce migration when
combined with podoplanin crosslinking (Figure 7B). These
results suggested that podoplanin acted downstream of VEGF-C
Figure 5. Time course of tube formation by LEC cultured with fibroblasts. A. Human dermal fibroblasts were grown to confluence on 12-well plates. 3
× 104 LEC were stained with 5 µM Cell Tracker Green and seeded onto the HDF monolayer in the presence of culture medium with (lower panels) or
without (upper panels) VEGF-C (300 ng/ml). Cultures were maintained at 37°C and 5% CO2 and imaged using a fluorescence microscope at 24 hour
intervals. Images are representative of three independent experiments. Scale bars represent 100 µm. B. Quantitation of tube length after 72 h with or
without VEGF-C. Data are mean ± SEM from three experiments. *p < 0.05 by paired t-test.
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receptor(s) and upstream of RhoA in effecting the migratory
response.
Discussion
We have shown that addition of platelets to LEC or antibody-induced
crosslinking of podoplanin on LEC both suppresses the pro-migratory
effects of VEGF. On the other hand, reduction in expression of
podoplanin induced an equivalent suppression of the response to
VEGF. These treatments inhibited responses to both VEGF-A and
VEGF-C, but none affected the substantial basal migration in the
absence of VEGF, nor did crosslinking inhibit increases in migration
induced by bFGF or EGF. Blockade of receptors VEGFR2 and
VEGFR3 indicated that these receptors primarily supported the
responses to VEGF-A and VEGF-C, respectively, although response
to VEGF-C appeared to utilize both receptors. Thus, podoplanin is a
Figure 6. Effects of Platelets and podoplanin crosslinking on networks of LEC formed on fibroblasts. A) Networks of LEC formed after 3 or 4 days of
co-culture with HDF plus VEGF-C (300 ng/ml), with or without addition of washed human platelets after 3 days. Images are representative of three
independent experiments. B) Networks of LEC formed after 3 or 4 days of co-culture with HDF plus VEGF-C (300 ng/ml), with or without addition of
antibodies that were nonspecific or which induced crosslinking of podoplanin. Images are representative of two or more independent experiments. C)
Quantitation of tube length from section A at day 4 in experiments where platelets were added at day 3 to networks treated with VEGF-C. Data are
mean ± SEM from three experiments, expressed relative to tube length at day 3. *p < 0.05 by paired t-test. D) Quantitation of tube length from section
B at day 4 in experiments where antibodies that were nonspecific or which induced crosslinking of podoplanin were added at day 3 to networks treated
with VEGF-C. Data are mean ± SEM from two to five experiments, expressed relative to tube length at day 3. *p < 0.05 by paired t-test compared to
untreated.
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regulator of LEC migration specific to VEGF and is able to modulate
signaling through VEGFR-2 and VEGFR3.
Platelets were also able to suppress migration of HMEC-1, an
immortalized endothelial cell line derived from dermal tissue
which express podoplanin, albeit at a lower level than LEC.
Interestingly, the pro-migratory effect of VEGF-C was less for
these cells than LEC, but platelets returned migration of both to
baseline level. Both cell types had significant basal migration
without VEGF, and for LEC at least, this was not dependent on
podoplanin expression or crosslinking. It seems, however, that the
addition of VEGF increased transmigration by a degree depend-
ing on the level of podoplanin expressed or the proportion of cells
expressing podoplanin. Subsequently, if the responding cells
expressing adequate podoplanin became non-responders when
podoplanin was ligated, the overall population migration would
return to the level without VEGF-C for either LEC or HMEC-1.
Put the other way, the trends suggest that only those cells expres-
sing podoplanin above a certain level would respond to VEGF
and have that response modified by ligation of podoplanin. These
trends thus further support the key role of podoplanin in regulat-
ing the response to VEGF-C.
We developed a “lymphatic network” formation assay, based
on the co-culture of LEC and HDF. This model was based on one
previously used with vascular endothelial cells (VEC) in the study
of angiogenesis [36–38], and we report the first description of
formation of comparable stable networks for LEC. Addition of
platelets to these networks or crosslinking of podoplanin caused
their disruption. Thus, overall, crosslinking of podoplanin
mimicked responses to platelets closely, and indeed, the effect
of platelets on migration was lost after reduction in expression of
podoplanin by siRNA. Migration of LEC was also suppressed
when murine platelets were added, but the effect was significantly
reduced when the platelets were derived from mice lacking
expression of CLEC-2. Taken together, the results strongly sug-
gest that the effects of platelets were mediated through cross-
linking of podoplanin by CLEC-2, which has previously been
shown to be able to fulfill that function [12,39].
Downstream of VEGFR, inhibition of RhoA, or of ROCK nulli-
fied migratory responses to VEGF-C. Interestingly, crosslinking of
podoplanin had no further effect when combinedwith these inhibitors.
Rho GTPases are well-described regulators of cell motility [40], and
these results indicate that podoplanin regulated signaling through
RhoA.
Our findings are broadly consistent with previous observations
on behavior of LEC. We recently reported that platelets or cross-
linking of podoplanin inhibited LEC migration in presence of
VEGFC and short-term formation of networks on Matrigel [12].
Osada et al., found similar effects of platelets on these responses
and showed that soluble agents released by platelets activated
through GpVI ligation could also inhibit migration and network
formation on Matrigel [13]. The relevance of the effects of sub-
stances released through GpVI ligation to the effects of podopla-
nin-CLEC-2 interaction is uncertain. In our studies, crosslinking
of podoplanin on LEC (where there would be no substances from
platelets) was similarly effective to platelets themselves, ruling
out an absolute requirement for released agents in effects
described. Others noted that knockdown of podoplanin in LEC
reduced their ability to migrate across a wound or form networks
on Matrigel [17,18]. In MDCK cells, overexpression of podopla-
nin increased active RhoA and phosphorylated ERM proteins
[15], while in LEC, podoplanin knockdown was associated with
a reduction in active RhoA but had no effect on the amount of
phosphorylated ERM proteins [16] We did not find any change in
phosphorylated ERM proteins after podoplanin knockdown, while
crosslinking podoplanin did not inhibit the increase in active
RhoA detected within 10 minutes or 10 hours after treatment
with VEGFC (data not shown). Others have suggested that the
action of podoplanin on ERM-phosphorylation operates via active
RhoA [15], which would be consistent with the action of RhoA
requiring podoplanin. Thus, two possibilities arise, in that podo-
planin might be required for the activation of RhoA itself or may
regulate RhoA function downstream of VEGF-R.
The observation that both loss of expression of podoplanin and
crosslinking of endogenous podoplanin had similar effects on
VEGF-induced migration suggests a requirement for signaling
through podoplanin downstream of VEGF-R that would be turned
off by podoplanin ligation. Interestingly, podoplanin crosslinking
or knockdown solely abrogated VEGF-mediated migration,
whereas responses to other growth factors remained unaffected.
This could be explained if VEGFR signaling to RhoA required
input from podoplanin, but signaling from the other growth fac-
tors to RhoA was via another route. It is also interesting that
podoplanin is required in LEC to respond to VEGF-A or VEGF-
C, while VEC which do not express podoplanin respond to
VEGF-A at least. This difference may arise from the different
combinations of VEGFR used by these cells (e.g., VEGFR1 and
VEGFR2 in VEC vs. VEGFR2 and VEGFR3 in LEC) or from
intrinsic differences in pathways downstream of the receptors in
the different cells [42].
It is notable that we could not achieve better than ~50% reduction
in surface expression of podoplanin using various combinations and
concentrations of siRNA. However, this result is consistent with the
Figure 7. Effects of inhibitors of RhoA signaling combined with podo-
planin crosslinking on LEC migration. A) LEC settled onto a Transwell
filter were treated with or without RhoA inhibitor CT04 (4 µg/ml), with
or without antibodies that induced podoplanin crosslinking, with or with-
out VEGF-C (300 ng/ml). The percentage of the LEC which had trans-
migrated after 24 h was analyzed. Data are mean ± SEM from three
experiments. ANOVA showed significant effects of VEGF-C (p < 0.05)
and treatment (p < 0.01). **=p < 0.01 compared to no treatment by
Dunnet test for VEGF-C-treated cells. B) LEC settled onto a Transwell
filter were treated with or without ROCK inhibitor Y27632 (100 µM),
with or without antibodies that induced podoplanin crosslinking, with
VEGF-C (300ng/ml). The percentage of the LEC which had transmi-
grated after 24 h was analyzed. Data are mean ± SEM from three or more
experiments. ANOVA showed significant effect of treatment (p < 0.01).
**=p < 0.01 compared to no treatment by Dunnett´s test.
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level in other reports judging by the unquantified Western blots
presented [17,18]. Nevertheless, this reduction in expression was
sufficient to negate the effect of VEGF on migration. That 50% of
podoplanin remained after 72 hour treatment with siRNA implies
that there is a long-lived portion of the constitutive podoplanin. A
possible explanation for the migration results is that there are “fast”
and “slow” turnover pools of podoplanin that have different func-
tional effects, or that the function of podoplanin changes with time
after expression. Thus, the long-lived pool of podoplanin may not be
linked to the signaling machinery for migration. However, the more
newly expressed pool or fast-turnover pool (not expressed after
treatment with siRNA) may be a key for the regulation of the
VEGF response.
It is also notable that the network formation assay used here,
based on the co-culture of LEC and HDF, is different from LEC
networks formed on Matrigel. In the Matrigel assay, networks
form on a surface of deposited growth factors and the networks
typically only persist for a few hours [41]. In contrast, networks
formed in co-cultures developed and persisted over four days.
There is also evidence that for VEC at least, the networks have
lumens, making this model more representative of endothelial
tube formation in vivo [36]. These stable networks were clearly
susceptible to the effects of platelets and podoplanin crosslinking.
The transfilter assay used for the majority of the studies showed
quite high levels of basal cell migration, which were relatively
insensitive to treatments other than VEGF. However, the assay
was robust in that we consistently observed significant effects of
VEGF and modifiers of its response. Overall, in 23 experiments,
the proportional increase from baseline with VEGF-C was 51 ±
8% (mean ± SEM). The finding that the basal migration was itself
consistently unaffected by platelets or podoplanin crosslinking
was a key in being able to show that these specifically affected
the response to VEGF-C.
A number of observations indicate the physiological signifi-
cance of the interactions analyzed here. Lack of podoplanin or
platelet-specific loss of CLEC-2 causes malformation of the lym-
phatics during development in utero, where platelet-LEC interac-
tions can be seen in the cardinal vein during the process of the
separation of the lymphatic system [5,7]. In adult mice, radiation
chimaeras reconstituted with CLEC-2-deficient bone marrow
exhibit blood-lymphatic mixing in the intestines, illustrating a
role for platelets in continuing repair and growth of the lymphatic
system [12]. Interactions between platelets and LEC can also be
observed near the junction of the thoracic duct and subclavian
vein in mice, where they appear to prevent leakage of blood into
the lymph [43]. Here, LEC migration was reduced when 107
platelets (equivalent to the content of about 50µl of blood) were
added to 3x104 endothelial cells coating a surface area of 30mm2.
In the assay, not all the platelets are likely to have actually
adhered and made effective contact, while in vivo, there is likely
to be a degree of flow, so that platelets are continually delivered,
making many contacts possible. In flowing blood, we have shown
that platelets are effectively marginated to the periphery close to
endothelium [44] and that high levels of deposition of platelets
occur when blood is flowed over LEC at low shear rates [45].
Thus, we believe that the conditions applied, although rather
remote from those in vivo, are a relevant representation of inter-
actions that could happen there, and that the changes in motility
noted are relevant to the development, growth, and repair of
lymphatics, which will include a component of LEC migration.
In conclusion, podoplanin which is highly expressed in LEC is
an essential regulator of the response to VEGF in these cells, but not
intrinsic motility or that stimulated by other growth factors. Platelets
are thus able to modulate the migration of lymphatic endothelial
cells and their ability to maintain stable networks by crosslinking
this ligand which in turn modulates signaling through the RhoA
pathway downstream of VEGFR-2 or -3. Our results suggest that
podoplanin ligation can represent a novel approach to modulate
LEC migration and tube formation in response to VEGF isoforms,
key processes during cancer- and inflammation-induced lymphan-
giogenesis [42,46]. Further studies are warranted to dissect the
potential therapeutic value of such an approach.
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